An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone

Shokei Kim-Mitsuyama, Hisao Ogawa, Kunihiko Matsui, Tomio Jinnouchi, Hideaki Jinnouchi, Kikuo Arakawa, Shokei Kim-Mitsuyama, Hisao Ogawa, Kunihiko Matsui, Tomio Jinnouchi, Hideaki Jinnouchi, Kikuo Arakawa

Abstract

The OSCAR study was a multicenter, prospective randomized open-label blinded end-point study of 1164 Japanese elderly hypertensive patients comparing the efficacy of angiotensin II receptor blocker (ARB) uptitration to an ARB plus calcium channel blocker (CCB) combination. In this prospective study, we performed prespecified subgroup analysis according to baseline estimated glomerular filtration rate (eGFR) with chronic kidney disease (CKD) defined as an eGFR <60 ml/min per 1.73 m(2). Blood pressure was lower in the combined therapy than in the high-dose ARB cohort in both groups with and without CKD. In patients with CKD, significantly more primary events (a composite of cardiovascular events and noncardiovascular death) occurred in the high-dose ARB group than in the combination group (30 vs. 16, respectively, hazard ratio 2.25). Significantly more cerebrovascular and more heart failure events occurred in the high-dose ARB group than in the combination group. In patients without CKD, however, the incidence of primary events was similar between the two treatments. The treatment-by-subgroup interaction was significant. Allocation to the high-dose ARB was a significant independent prognostic factor for primary events in patients with CKD. Thus, the ARB plus CCB combination conferred greater benefit in prevention of cardiovascular events in patients with CKD compared with high-dose ARB alone. Our findings provide new insight into the antihypertensive strategy for elderly hypertensive patients with CKD.

Trial registration: ClinicalTrials.gov NCT00134160.

Figures

Figure 1
Figure 1
Time course of systolic and diastolic blood pressure (BP) in high-dose angiotensin II receptor blocker (ARB) and ARB plus calcium channel blocker (CCB) combination groups in patients with chronic kidney disease (CKD) and without CKD. (a) Indicates patients with CKD and (b) indicates patients without CKD.
Figure 2
Figure 2
Kaplan–Meier curves for primary composite end points during the follow-up period in patients with chronic kidney disease (CKD) and without CKD. In (a), the number of patients in high-dose angiotensin II receptor blocker (ARB) and ARB plus calcium channel blocker (CCB) combination groups were 181 and 172, respectively, and there were 30 and 16 primary end points in high-dose ARB and ARB plus CCB combination groups, respectively. In (b), the number of primary end points was 27 in 354 patients assigned high-dose ARB and 32 in 371 patients assigned ARB plus CCB combination. CI, confidence interval; HR, hazard ratio.
Figure 3
Figure 3
Hazard ratios (HRs) and 95% confidence intervals (CIs) for the primary composite end points and secondary end points in patients with chronic kidney disease (CKD) and patients without CKD at baseline. (a) Indicates patients with CKD and (b) indicates patients without CKD. The HRs and 95% CIs were derived from a stratified Cox proportional hazards model, taking into account sex, age, and baseline cardiovascular disease and type 2 diabetes. The P-values were derived from a log-rank test, stratified by sex, age, and baseline cardiovascular disease and type 2 diabetes. ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CV, cardiovascular.
Figure 4
Figure 4
Time course of changes in estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease (CKD) and without CKD during the follow-up period. (a) Indicates patients with CKD and (b) indicates patients without CKD. ARB, angiotensin II receptor blocker; CCB, calcium channel blocker. Data represent the mean±s.d.
Figure 5
Figure 5
Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of achieved systolic blood pressure (BP) and diastolic BP levels for incidence of primary composite end points in total patients with available estimated glomerular filtration rate data (n=1078). The achieved BP on a per-patient basis was defined as the mean value of all BP values during the follow-up period. The reference category was (a) <130 mm Hg for systolic BP and (b) <70 mm Hg for diastolic BP. DBP, diastolic BP; SBP, systolic BP.

References

    1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305.
    1. Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–1271.
    1. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121–1129.
    1. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47–55.
    1. Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228–236.
    1. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663.
    1. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001;12:218–225.
    1. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629–636.
    1. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–210.
    1. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–1295.
    1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266.
    1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169.
    1. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
    1. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
    1. Solomon SD, Rice MM, AJ K, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114:26–31.
    1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252.
    1. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of hypertension (ESH) and of the European Society of cardiology (ESC) Eur Heart J. 2007;2007;28:1462–1536.
    1. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2009) Hypertens Res. 2009;32:3–107.
    1. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878.
    1. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840–1848.
    1. Ogawa H, Kim-Mitsuyama S, Matsui K, et al. Angiotensin II receptor blocker-based therapy in Japanese elderly high-risk hypertensive patients Am J Med 2012. e-pub ahead of print 16 April 2012.
    1. Ogawa H, Kim-Mitsuyama S, Jinnouchi T, et al. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160) Hypertens Res. 2009;32:575–580.
    1. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470.
    1. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300.
    1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
    1. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386–392.
    1. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173–1181.
    1. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428.
    1. Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol. 2005;16:474–481.
    1. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19:999–1007.
    1. Hermida RC, Ayala DE, Mojon A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22:2313–2321.
    1. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–992.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa